ST2 in patients with severe aortic stenosis and heart failur
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
ST2 is a circulating biomarker that is well established for predicting outcomes in heart failure (HF). This is the first study to look at ST2 concentrations in optimally treated patients with stable but significant left ventricular systolic dysfunction (LVSD) compared to patients with severe aortic stenosis (AS).

The serum ST2 concentrations are elevated to similar levels in patients with severe LVSD and in the population of patients with severe AS who underwent TAVI. The concentrations were highest in patients with severe LVSD and severe AS. This is the first study to compare ST2 concentrations in optimally treated patients with stable but significant LV dysfunction with those in patients with severe AS. Raised ST2 concentrations from increased biomechanical stress on the myocardium in the context of severe AS may be a marker for subclinical or clinical LV dysfunction.

Ongoing biomarker research in this area should not focus solely on replacing NT-proBNP or even troponin, but rather on investigating early pathophysiological changes in the myocardium, which may lead to future therapeutic targets. It is tempting to speculate that early detection of disease progression using novel biomarkers or significant changes in interval testing may be of future clinical relevance, but larger prospective studies will be required to address these gaps in knowledge.

Two cohorts were retrospectively studied: 94 patients undergoing transcatheter aortic valve implantation for severe AS (63 with normal ejection fraction [EF] and 31 with reduced EF), and 50 patients with severe LVSD from non-valvular causes. ST2 pre-procedural samples were taken, and repeated again at 3 and 6 months. Patients were followed-up for 2 years. Baseline concentrations of soluble ST2 did not differ significantly between the HF group and AS group with normal EF. However, in the AS group with a low EF, ST2 concentrations were significantly higher than in the HF group. New York Heart Association class IV HF, baseline N-terminal pro-B-type natriuretic peptide, and gender were all independent predictors of soluble ST2 (sST2) baseline concentrations.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105079/
Like
Comment
Share